Life sciences firm 'set for growth' after fresh deal

A life sciences firm says it is “well-positioned for growth” after a contract win pushed its order book to new heights. 

Aptamer Group has secured a £617,000 agreement with a “top five” pharmaceutical company.

Bosses say the partnership has bolstered the York-based operator’s order book to £1.75 million – a 46 per cent rise on last year – leaving it primed to “deliver sustained revenue growth”.

Under the terms of its latest deal, they add the company will develop its Optimer-branded antibody alternative molecules against three drug targets and support biological sample test advances.

Dr Arron Tolley, chief executive, said: “The decision by a top five pharmaceutical partner to commission this large-scale, multi-target programme follows the successful completion of a proof-of-concept project.

“It means the group now has signed contract value of £1.75 million for this financial year, with eight months still remaining. 

“As such, we are well positioned to build on last year’s performance and deliver sustained revenue growth. 

“We continue to build a robust foundation of repeat business with leading pharmaceutical partners, converting our commercial pipeline into long-term value for shareholders.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.